What are the contraindications for denosumab therapy?

Contraindications to Denosumab

Denosumab is absolutely contraindicated in patients with hypocalcemia, pregnancy, and known hypersensitivity to the drug. 1

Absolute Contraindications

Hypocalcemia

Pre-existing hypocalcemia must be corrected before initiating denosumab therapy. 2 This is the most critical contraindication because denosumab can cause severe and even fatal hypocalcemia. 1 Patients with hypocalcemia often have underlying conditions such as hypoparathyroidism or osteomalacia. 2

Pregnancy

Denosumab is contraindicated in pregnant women due to risk of fetal harm. 1 Animal studies in cynomolgus monkeys showed increased fetal loss, stillbirths, postnatal mortality, absent lymph nodes, abnormal bone growth, and decreased neonatal growth when exposed to denosumab during pregnancy. 1 Pregnancy testing should be performed in women of reproductive potential before initiating treatment. 1

Hypersensitivity

Patients with a history of systemic hypersensitivity to any component of denosumab are contraindicated from receiving the drug. 1 Documented reactions have included anaphylaxis, facial swelling, and urticaria. 1

Critical Precautions and High-Risk Populations

Advanced Chronic Kidney Disease (eGFR <30 mL/min)

While not an absolute contraindication, patients with advanced chronic kidney disease, including those on dialysis, are at substantially greater risk for severe, life-threatening, and even fatal hypocalcemia. 1 Unlike bisphosphonates, denosumab can be used in renal insufficiency without dose adjustment 2, but this comes with significant caveats:

• Monitor serum calcium weekly for the first month after administration, then monthly thereafter 1
• Evaluate for chronic kidney disease-mineral bone disorder (CKD-MBD) with intact PTH, serum calcium, 25(OH) vitamin D, and 1,25(OH)2 vitamin D before treatment 1
• Consider assessing bone turnover status with serum markers or bone biopsy 1
• Treatment should be supervised by a provider experienced in managing CKD-MBD 1
• Severe hypocalcemia in this population has resulted in hospitalization and fatal cases 1

Organ Transplant Recipients

Denosumab is not recommended in organ transplant patients receiving multiple immunosuppressive agents due to inadequate safety data on infection risk. 3 The 2017 American College of Rheumatology guidelines specifically recommend against denosumab in this population. 3

Women of Childbearing Potential

For women who could become pregnant, denosumab should only be used if:

• They do not plan pregnancy during treatment
• They are using effective birth control or are not sexually active
• They have been counseled about potential fetal harm 3

Bisphosphonates or teriparatide are preferred alternatives in this population. 3

Mandatory Pre-Treatment Requirements

Before initiating denosumab, the following must be addressed:

1. Correct any pre-existing hypocalcemia 1
2. Ensure adequate calcium (≥1000 mg daily) and vitamin D (≥400 IU daily) supplementation 2, 1
3. Assess serum calcium and mineral levels (phosphorus, magnesium) in patients predisposed to hypocalcemia (those with history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, small intestine excision) 1
4. Perform baseline dental evaluation for high-risk individuals to reduce osteonecrosis of the jaw risk 4

Common Pitfalls to Avoid

• Never discontinue denosumab abruptly without transitioning to another antiresorptive agent (typically a bisphosphonate), as this causes rapid bone loss and increased risk of multiple vertebral fractures 2, 5
• Do not assume renal insufficiency is a contraindication—unlike bisphosphonates, denosumab can be used, but requires intensive calcium monitoring 2, 1
• Do not overlook calcium supplementation—this is mandatory, not optional, for all patients receiving denosumab 1